315 related articles for article (PubMed ID: 33632456)
1. Advances and ongoing controversies in PFO closure and cryptogenic stroke.
Cheng T; Gonzalez JB; Testai FD
Handb Clin Neurol; 2021; 177():43-56. PubMed ID: 33632456
[TBL] [Abstract][Full Text] [Related]
2. Advances and Ongoing Controversies in Patent Foramen Ovale Closure and Cryptogenic Stroke.
Gonzalez JB; Testai FD
Neurol Clin; 2021 Feb; 39(1):51-69. PubMed ID: 33223089
[TBL] [Abstract][Full Text] [Related]
3. Transcatheter Closure of Patent Foramen Ovale: Randomized Trial Update.
Arfaras-Melainis A; Palaiodimos L; Mojadidi MK
Interv Cardiol Clin; 2019 Oct; 8(4):341-356. PubMed ID: 31445719
[TBL] [Abstract][Full Text] [Related]
4. Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 Trials.
Kent DM; Saver JL; Ruthazer R; Furlan AJ; Reisman M; Carroll JD; Smalling RW; Jüni P; Mattle HP; Meier B; Thaler DE
Stroke; 2020 Oct; 51(10):3119-3123. PubMed ID: 32921262
[TBL] [Abstract][Full Text] [Related]
5. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I (Evaluation of the STARFlex Septal Closure System in Patients With a Stroke and/or Transient Ischemic Attack Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale) trial.
Elmariah S; Furlan AJ; Reisman M; Burke D; Vardi M; Wimmer NJ; Ling S; Chen X; Kent DM; Massaro J; Mauri L;
JACC Cardiovasc Interv; 2014 Aug; 7(8):913-20. PubMed ID: 25147037
[TBL] [Abstract][Full Text] [Related]
6. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
[TBL] [Abstract][Full Text] [Related]
7. The role of device closure of patent foramen ovale in patients with cryptogenic stroke.
Fukutomi M; Wilkins B; Søndergaard L
J Intern Med; 2020 Oct; 288(4):400-409. PubMed ID: 32812297
[TBL] [Abstract][Full Text] [Related]
8. Patent foramen ovale closure in the management of cryptogenic stroke: a review of current literature and guideline statements.
Elzanaty AM; Patel N; Sabbagh E; Eltahawy EA
Curr Med Res Opin; 2021 Mar; 37(3):377-384. PubMed ID: 33460329
[TBL] [Abstract][Full Text] [Related]
9. Propensity-score matched analysis of patent foramen ovale closure in real-world study cohort with cryptogenic ischemic stroke.
Low CE; Teo YN; Teo YH; Lim ICZ; Rana S; Lee YQ; Chen X; Fang JT; Lam HH; Ong K; Yang J; Kuntjoro I; Low TT; Lee EC; Sharma VK; Yeo LL; Sia CH; Tan BY; Lim Y
J Stroke Cerebrovasc Dis; 2023 Dec; 32(12):107407. PubMed ID: 37804781
[TBL] [Abstract][Full Text] [Related]
10. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
Wiktor DM; Carroll JD
Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
[TBL] [Abstract][Full Text] [Related]
11. Closure of patent foramen ovale or medical therapy alone for secondary prevention of cryptogenic cerebrovascular events.
Fortuni F; Crimi G; Leonardi S; Angelini F; Raisaro A; Lanzarini LF; Oltrona Visconti L; Ferrario M; De Ferrari GM
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):373-381. PubMed ID: 29708911
[TBL] [Abstract][Full Text] [Related]
12. PFO closure vs. medical therapy in cryptogenic stroke or transient ischemic attack: a systematic review and meta-analysis.
Ntaios G; Papavasileiou V; Makaritsis K; Michel P
Int J Cardiol; 2013 Oct; 169(2):101-5. PubMed ID: 24041984
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous closure of patent foramen ovale in patients with cryptogenic embolism: a network meta-analysis.
Stortecky S; da Costa BR; Mattle HP; Carroll J; Hornung M; Sievert H; Trelle S; Windecker S; Meier B; Jüni P
Eur Heart J; 2015 Jan; 36(2):120-8. PubMed ID: 25112661
[TBL] [Abstract][Full Text] [Related]
14. Long-term experience and outcomes with transcatheter closure of patent foramen ovale.
Inglessis I; Elmariah S; Rengifo-Moreno PA; Margey R; O'Callaghan C; Cruz-Gonzalez I; Baron S; Mehrotra P; Tan TC; Hung J; Demirjian ZN; Buonanno FS; Ning M; Silverman SB; Cubeddu RJ; Pomerantsev E; Schainfeld RM; Dec GW; Palacios IF
JACC Cardiovasc Interv; 2013 Nov; 6(11):1176-83. PubMed ID: 24262618
[TBL] [Abstract][Full Text] [Related]
15. Current Dataset for Patent Foramen Ovale Closure in Cryptogenic Stroke: Randomized Clinical Trials and Observational Studies.
Odunukan OW; Price MJ
Interv Cardiol Clin; 2017 Oct; 6(4):525-538. PubMed ID: 28886843
[TBL] [Abstract][Full Text] [Related]
16. Interventional prevention of paradoxical embolism as the gold standard: End of discussion?
Nykl R; Precek J; Sluka M; Hudec S; Richter D; Heinc P; Taborsky M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2021 Sep; 165(3):241-248. PubMed ID: 34158673
[TBL] [Abstract][Full Text] [Related]
17. Cryptogenic Stroke and Patent Foramen Ovale Risk Assessment.
Melkumova E; Thaler DE
Interv Cardiol Clin; 2017 Oct; 6(4):487-493. PubMed ID: 28886840
[TBL] [Abstract][Full Text] [Related]
18. Patent foramen ovale (PFO) closure versus medical therapy for prevention of recurrent stroke in patients with prior cryptogenic stroke: A systematic review and meta-analysis of randomized controlled trials.
Akobeng AK; Abdelgadir I; Boudjemline Y; Hijazi ZM
Catheter Cardiovasc Interv; 2018 Jul; 92(1):165-173. PubMed ID: 29602258
[TBL] [Abstract][Full Text] [Related]
19. Device closure of patent foramen ovale versus medical therapy in cryptogenic stroke: a systematic review and meta-analysis.
Khan AR; Bin Abdulhak AA; Sheikh MA; Khan S; Erwin PJ; Tleyjeh I; Khuder S; Eltahawy EA
JACC Cardiovasc Interv; 2013 Dec; 6(12):1316-23. PubMed ID: 24139929
[TBL] [Abstract][Full Text] [Related]
20. Device Closure of Patent Foramen Ovale for Cryptogenic Stroke: Patient Selection and Outcomes According to New Randomized Trials.
Carroll AM; Carroll JD
Curr Cardiol Rep; 2019 Apr; 21(6):48. PubMed ID: 31011896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
